{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T23:08:34Z","timestamp":1768864114299,"version":"3.49.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-025-01377-7","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:34:50Z","timestamp":1768811690000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in Melanoma: A Dynamic Frontier in Cancer Treatment"],"prefix":"10.1007","volume":"27","author":[{"given":"Azhar","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6552-8795","authenticated-orcid":false,"given":"Mohammed","family":"Alahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1268-3115","authenticated-orcid":false,"given":"Zakaria","family":"Khawaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Eissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0367-4616","authenticated-orcid":false,"given":"Sara","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1377_CR1","volume-title":"Melanoma pathology","author":"Y Puckett","year":"2025","unstructured":"Puckett Y, Wilson AM, Farci F, Thevenin C. In: StatPearls, editor. Melanoma pathology. Treasure Island [FL]: StatPearls Publishing; 2025."},{"issue":"1","key":"1377_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"1377_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.2214\/AJR.16.16800","volume":"208","author":"VK Wong","year":"2017","unstructured":"Wong VK, Lubner MG, Menias CO, Mellnick VM, Kennedy TA, Bhalla S, et al. Clinical and imaging features of noncutaneous melanoma. AJR Am J Roentgenol. 2017;208(5):942\u201359. https:\/\/doi.org\/10.2214\/AJR.16.16800.","journal-title":"AJR Am J Roentgenol"},{"key":"1377_CR4","volume-title":"StatPearls. Treasure Island","author":"JB Heistein","year":"2025","unstructured":"Heistein JB, Acharya U, Mukkamalla SKR. Malignant melanoma. StatPearls. Treasure Island. [FL]: StatPearls Publishing; 2025."},{"key":"1377_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153837","author":"RC Wang","year":"2023","unstructured":"Wang RC, Wang Z. Precision medicine: disease subtyping and tailored treatment. Cancers. 2023. https:\/\/doi.org\/10.3390\/cancers15153837.","journal-title":"Cancers"},{"key":"1377_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115370","author":"S Kado","year":"2025","unstructured":"Kado S, Komine M. Recent advances in molecular research and treatment for melanoma in Asian populations. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26115370.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1377_CR7","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3390\/cancers15041106","volume":"15","author":"A Knight","year":"2023","unstructured":"Knight A, Karapetyan L, Kirkwood JM. Immunotherapy in melanoma: recent advances and future directions. Cancers. 2023;15(4):1106.","journal-title":"Cancers"},{"key":"1377_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1529-8019.2005.00052.x","volume":"191","author":"AA Tarhini","year":"2006","unstructured":"Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther. 2006;191:19\u201325.","journal-title":"Dermatol Ther"},{"issue":"7528","key":"1377_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"1","key":"1377_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","volume":"392","author":"JD Wolchok","year":"2024","unstructured":"Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, Dummer R, Butler MO, Hill AG, Postow MA. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2024;392(1):11.","journal-title":"N Engl J Med"},{"key":"1377_CR11","doi-asserted-by":"crossref","unstructured":"Weiss SA, Wolchok JD, Sznol M. Immunotherapy of melanoma: facts and hopes. Clin Cancer Res. 2019;25(17):5191\u2009\u2013\u2009201.","DOI":"10.1158\/1078-0432.CCR-18-1550"},{"key":"1377_CR12","unstructured":"Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis."},{"key":"1377_CR13","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","volume":"726","author":"SY Kim","year":"2015","unstructured":"Kim SY, Kim SN, Hahn HJ, Lee YW, Choe YB, Ahn KJ. Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. J Am Acad Dermatol. 2015;726:1036\u201346.","journal-title":"J Am Acad Dermatol"},{"key":"1377_CR14","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1002\/ijc.30241","volume":"14012","author":"R Maxwell","year":"2017","unstructured":"Maxwell R, Garzon-Muvdi T, Lipson EJ, Sharfman WH, Bettegowda C, Redmond KJ, Kleinberg LR, Ye X, Lim M. BRAF\u2010V600 mutational status affects recurrence patterns of melanoma brain metastasis. Int J Cancer. 2017;14012:2716\u201327.","journal-title":"Int J Cancer"},{"issue":"11","key":"1377_CR15","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrd3847","volume":"11","author":"G Bollag","year":"2012","unstructured":"Bollag G, Tsai J, Zhang J, Zhang C, Ibrahim P, Nolop K, et al. Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov. 2012;11(11):873\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"1377_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","volume":"13S4","author":"JD Wolchok","year":"2008","unstructured":"Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13S4:2\u20139.","journal-title":"Oncologist"},{"key":"1377_CR17","doi-asserted-by":"publisher","first-page":"880876","DOI":"10.3389\/fonc.2022.880876","volume":"12","author":"J Thornton","year":"2022","unstructured":"Thornton J, Chhabra G, Singh CK, Guzm\u00e1n-P\u00e9rez G, Shirley CA, Ahmad N. Mechanisms of immunotherapy resistance in cutaneous melanoma: recognizing a shapeshifter. Front Oncol. 2022;12:880876.","journal-title":"Front Oncol"},{"key":"1377_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.","journal-title":"Front Pharmacol"},{"key":"1377_CR19","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:731798.","journal-title":"Front Pharmacol"},{"key":"1377_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41568-022-00442-9","volume":"224","author":"S Kalaora","year":"2022","unstructured":"Kalaora S, Nagler A, Wargo JA, Samuels Y. Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022;224:195\u2013207.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"1377_CR21","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3390\/cancers12071994","volume":"12","author":"AA Testori","year":"2020","unstructured":"Testori AA, Chiellino S, van Akkooi AC. Adjuvant therapy for melanoma: past, current, and future developments. Cancers. 2020;12(7):1994.","journal-title":"Cancers"},{"issue":"1","key":"1377_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 Blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6(1):39.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1377_CR23","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.3390\/ijms25126532","volume":"25","author":"R Reschke","year":"2024","unstructured":"Reschke R, Enk AH, Hassel JC. Chemokines and cytokines in immunotherapy of melanoma and other tumors: from biomarkers to therapeutic targets. Int J Mol Sci. 2024;25(12):6532.","journal-title":"Int J Mol Sci"},{"key":"1377_CR24","doi-asserted-by":"crossref","unstructured":"Cai J, Wang D, Zhang G, Guo X. The role of PD-1\/PD-L1 axis in Treg development and function: implications for cancer immunotherapy. OncoTargets Therapy 2019;8437\u201345.","DOI":"10.2147\/OTT.S221340"},{"issue":"9","key":"1377_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/S1470-2045(17)30428-X","volume":"18","author":"GV Long","year":"2017","unstructured":"Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017;18(9):1202\u201310.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1377_CR26","doi-asserted-by":"publisher","first-page":"1903827","DOI":"10.1080\/21645515.2021.1903827","volume":"18","author":"L Tagliaferri","year":"2022","unstructured":"Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Cas\u00e0 C, Di Stefani A, Pagliara MM, D\u2019Aviero A, Schinzari G, Chiesa S, Mazzarella C. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccines Immunotherapeutics. 2022;18(3):1903827.","journal-title":"Hum Vaccines Immunotherapeutics"},{"issue":"2","key":"1377_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CMR.0000000000000800","volume":"32","author":"G Yin","year":"2022","unstructured":"Yin G, Guo W, Huang Z, Chen X. Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis. Melanoma Res. 2022;32(2):71\u20138.","journal-title":"Melanoma Res"},{"key":"1377_CR28","unstructured":"Anvari A, Sasanpour P, Kheradmardi MR. Radiotherapy and immunotherapy in melanoma brain metastases. Hematol Oncol Stem Cell Ther. 2021."},{"key":"1377_CR29","doi-asserted-by":"crossref","unstructured":"Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. InSeminars in cancer biology 2009 Oct 1 (Vol. 19, No. 5, pp. 329\u201337). Academic Press.","DOI":"10.1016\/j.semcancer.2009.05.003"},{"issue":"1","key":"1377_CR30","first-page":"14","volume":"1","author":"GW Prager","year":"2012","unstructured":"Prager GW, Poettler M, Unseld M, Zielinski CC. Angiogenesis in cancer: anti-VEGF escape mechanisms. Transl Lung Cancer Res. 2012;1(1):14.","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"1377_CR31","first-page":"534","volume":"17","author":"P Rajabi","year":"2012","unstructured":"Rajabi P, Neshat A, Mokhtari M, Rajabi MA, Eftekhari M, Tavakoli P. The role of VEGF in melanoma progression. J Res Med Sci. 2012;17(6):534.","journal-title":"J Res Med Sci"},{"key":"1377_CR32","doi-asserted-by":"crossref","unstructured":"Yang Y, Cao Y. The impact of VEGF on cancer metastasis and systemic disease. InSeminars in cancer biology 2022 Nov 1 (Vol. 86, pp. 251\u201361). Academic Press.","DOI":"10.1016\/j.semcancer.2022.03.011"},{"issue":"7","key":"1377_CR33","doi-asserted-by":"publisher","first-page":"e157347","DOI":"10.1172\/jci.insight.157347","volume":"8","author":"TT Tran","year":"2023","unstructured":"Tran TT, Caulfield J, Zhang L, Schoenfeld D, Djureinovic D, Chiang VL, Oria V, Weiss SA, Olino K, Jilaveanu LB, Kluger HM. Lenvatinib or anti-VEGF in combination with anti\u2013PD-1 differentially augments antitumor activity in melanoma. JCI Insight. 2023;8(7):e157347.","journal-title":"JCI Insight"},{"issue":"14","key":"1377_CR34","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO-24-02219","volume":"43","author":"SA Weiss","year":"2025","unstructured":"Weiss SA, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, Eroglu Z, Khushalani NI, Hegde U, Cohen J, Sznol M. Phase II trial of pembrolizumab in combination with bevacizumab for untreated melanoma brain metastases. J Clin Oncol. 2025;43(14):1685\u201394.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1377_CR35","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-22-1528","volume":"28","author":"L Mao","year":"2022","unstructured":"Mao L, Fang M, Chen Y, Wei X, Cao J, Lin J, Zhang P, Chen L, Cao X, Chen Y, Guo J. Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study. Clin Cancer Res. 2022;28(21):4642\u20138.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1377_CR36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658\u201370.","journal-title":"Nat Biotechnol"},{"key":"1377_CR37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"10710","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara H, Ino Y, Todo T. Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci. 2016;10710:1373\u20139.","journal-title":"Cancer Sci"},{"key":"1377_CR38","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"3325","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;3325:2780\u20138.","journal-title":"J Clin Oncol"},{"key":"1377_CR39","doi-asserted-by":"crossref","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109-19.e10.","DOI":"10.1016\/j.cell.2017.08.027"},{"issue":"3","key":"1377_CR40","first-page":"179","volume":"11","author":"I Melero","year":"2014","unstructured":"Melero I, Gaudemack G, Gerritsen W, Soria JC, Cegarra-Navarro JG, Mellado B, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014;11(3):179\u201390.","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"1377_CR41","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1073\/pnas.101136398","volume":"98","author":"T Todo","year":"2001","unstructured":"Todo T, Martuza RL, Rabkin SD, Johnson PA. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A. 2001;98(17):6396\u2013401.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1377_CR42","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"104","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune-stimulating, and anti-tumour properties. Gene Ther. 2003;104:292\u2013303.","journal-title":"Gene Ther"},{"key":"1377_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"222","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014;222:251\u20136.","journal-title":"Mol Ther"},{"key":"1377_CR44","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"3422","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene Laherparepvec in combination with ipilimumab in untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;3422:2619\u201326.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1377_CR45","first-page":"2037","volume":"68","author":"W Leung","year":"2019","unstructured":"Leung W, Brown MP. Impact of MHC class i expression on oncolytic virotherapy and combination immunotherapy strategies. Cancer Immunol Immunother. 2019;68(12):2037\u201348.","journal-title":"Cancer Immunol Immunother"},{"key":"1377_CR46","first-page":"112233","volume":"14","author":"MA Zolaly","year":"2023","unstructured":"Zolaly MA, Al-Anazi MR, Alhazmi AM, AlMalki KA, Al-Shahrani FA. Oncolytic viruses as personalized immunotherapy for melanoma and other solid tumors: recent advances and biomarker development. Front Immunol. 2023;14:112233.","journal-title":"Front Immunol"},{"key":"1377_CR47","first-page":"688","volume":"21","author":"L Chen","year":"2016","unstructured":"Chen L, Wang S, Yang G, Chen W. Oncolytic viruses: molecular engineering and clinical applications. Front Biosci. 2016;21:688\u2013702.","journal-title":"Front Biosci"},{"key":"1377_CR48","first-page":"431","volume":"324","author":"M Armstrong","year":"2009","unstructured":"Armstrong M, Redman J, Kottke T, Diaz RM, Willmon C, Qiao J, et al. Intratumoral injection of dendritic cells enhances the therapeutic efficacy of oncolytic virotherapy. J Immunother. 2009;324:431\u20139.","journal-title":"J Immunother"},{"issue":"10","key":"1377_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"1377_CR50","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687\u201395.","journal-title":"J Clin Invest"},{"key":"1377_CR51","unstructured":"Beyond Immunotherapy. Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers - Scientific Figure on ResearchGate. Available from: https:\/\/www.researchgate.net\/figure\/The-dual-anti-tumor-mechanism-of-action-of-T-VEC-Initially-T-VEC-infects-tumor-cells_fig1_361223950. Accessed 29 Jun 2025."},{"issue":"23","key":"1377_CR52","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189\u201399.","journal-title":"N Engl J Med"},{"issue":"3","key":"1377_CR53","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","volume":"17","author":"HL Kaufman","year":"2010","unstructured":"Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718\u201330.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"1377_CR54","first-page":"613","volume":"17","author":"S Gujar","year":"2018","unstructured":"Gujar S, Pol J, Kroemer G, Rabkin SD, Delwar ZM. Oncolytic virus therapy: new immunotherapeutic approaches to treat cancer. Nat Rev Drug Discov. 2018;17(9):613\u201332.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1377_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","volume":"7","author":"RH Andtbacka","year":"2019","unstructured":"Andtbacka RH, Collichio F, Harrington KJ, Middleton MR, Downey G, \u00d6hrling K, et al. Final analyses of optim: A randomized phase III trial of talimogene Laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013IV melanoma. J Immunother Cancer. 2019;7(1):145. OPTiM trial investigated the role of T-VEC in improving outcomes among patients with unresectable stages III and IV melanoma. The outcomes of this trial were optimistic with considerable positive improvements in OS.","journal-title":"J Immunother Cancer"},{"key":"1377_CR56","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"2715","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor\u2013encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;2715:5763\u201371.","journal-title":"J Clin Oncol"},{"key":"1377_CR57","unstructured":"U.S. Food & drug Administration. FDA approves talimogene Laherparepvec for melanoma. FDA News Release; 2015."},{"issue":"13","key":"1377_CR58","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I, Milhem MM, Collichio F, Delman KA, et al. Patterns of clinical response with talimogene Laherparepvec in patients with melanoma treated in the optim phase III trial. Ann Surg Oncol. 2016;23(13):4169\u201377.","journal-title":"Ann Surg Oncol"},{"key":"1377_CR59","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"3617","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem M, Glaspy J, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene Laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced melanoma. J Clin Oncol. 2018;3617:1658\u201367.","journal-title":"J Clin Oncol"},{"key":"1377_CR60","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"3422","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al. Talimogene Laherparepvec in combination with pembrolizumab in untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol. 2016;3422:2619\u201326.","journal-title":"J Clin Oncol"},{"issue":"226","key":"1377_CR61","doi-asserted-by":"publisher","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","volume":"6","author":"D Zamarin","year":"2014","unstructured":"Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014;6(226):226ra32.","journal-title":"Sci Transl Med"},{"key":"1377_CR62","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O et al. MASTERKEY-265\/KEYNOTE-034: phase 3 trial of talimogene Laherparepvec [T-VEC] plus pembrolizumab vs pembrolizumab alone for advanced melanoma. J Clin Oncol. 2021;39:9503."},{"key":"1377_CR63","doi-asserted-by":"crossref","unstructured":"Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L. Randomized, double-blind, placebo-controlled, global phase III trial of talimogene Laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol. 2023;41(3):528-40.","DOI":"10.1200\/JCO.22.00343"},{"issue":"9","key":"1377_CR64","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1172\/JCI80009","volume":"125","author":"CJ Melief","year":"2015","unstructured":"Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401\u201312.","journal-title":"J Clin Invest"},{"key":"1377_CR65","doi-asserted-by":"crossref","unstructured":"Bommareddy PK, Patel A, Hossain S, Kaufman HL. Talimogene Laherparepvec [T-VEC] and Other Oncolytic Viruses for the Treatment of Melanoma. Am J Clin Dermatol. 2017;18(1):1\u201315. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27988837","DOI":"10.1007\/s40257-016-0238-9"},{"issue":"1","key":"1377_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1377_CR67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.coi.2009.03.002","volume":"21","author":"SA Rosenberg","year":"2009","unstructured":"Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233\u201340.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"1377_CR68","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2217\/imt-2016-0112","volume":"9","author":"JE Cohen","year":"2017","unstructured":"Cohen JE, Merims S, Frank S, Engelstein R, Peretz T, Lotem M. Adoptive cell therapy: past, present and future. Immunotherapy. 2017;9(2):183\u201396.","journal-title":"Immunotherapy"},{"issue":"17","key":"1377_CR69","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.3390\/cancers14174160","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, Wu X, Chen Y, Li M, Chen M, Li X. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14(17):4160.","journal-title":"Cancers"},{"issue":"3","key":"1377_CR70","doi-asserted-by":"publisher","first-page":"e008640","DOI":"10.1136\/jitc-2023-008640","volume":"12","author":"VA Fern\u00e1ndez","year":"2024","unstructured":"Fern\u00e1ndez VA, Mart\u00ednez PB, Granh\u00f8j JS, Borch TH, Donia M, Svane IM. Biomarkers for response to TIL therapy: a comprehensive review. J Immunother Cancer. 2024;12(3):e008640.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1377_CR71","doi-asserted-by":"publisher","first-page":"e005755","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10(12):e005755.","journal-title":"J Immunother Cancer"},{"key":"1377_CR72","unstructured":"Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM. Long-Term efficacy and safety of lifileucel Tumor-Infiltrating lymphocyte cell therapy in patients with advanced melanoma: A 5-Year analysis of the C-144-01 study. J Clin Oncol. 2025;2:JCO\u201325."},{"issue":"19","key":"1377_CR73","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","volume":"31","author":"L Hu","year":"2025","unstructured":"Hu L, Fan C, Bross P, Das A, Cho ES, Knudson KM, et al. FDA approval summary: lifileucel for unresectable or metastatic melanoma previously treated with an anti\u2013PD-1\u2013based immunotherapy. Clin Cancer Res. 2025;31(19):4004\u20139.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1377_CR74","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"1377_CR75","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.adcanc.2022.100035","volume":"4","author":"U Ahmad","year":"2022","unstructured":"Ahmad U, Khan Z, Ualiyeva D, Amissah OB, Noor Z, Khan A, Zaman N, Khan M, Khan A, Ali B. Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Adv Cancer Biology-Metastasis. 2022;4:100035.","journal-title":"Adv Cancer Biology-Metastasis"},{"issue":"1","key":"1377_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","volume":"10","author":"Z Wang","year":"2017","unstructured":"Wang Z, Wu Z, Liu Y, Han W. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1377_CR77","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/ijms21113906","volume":"21","author":"A Ahmad","year":"2020","unstructured":"Ahmad A, Uddin S, Steinhoff M. CAR-T cell therapies: an overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large B-cell lymphomas. Int J Mol Sci. 2020;21(11):3906.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1377_CR78","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.3390\/cells10061450","volume":"10","author":"T Soltantoyeh","year":"2021","unstructured":"Soltantoyeh T, Akbari B, Karimi A, Mahmoodi Chalbatani G, Ghahri-Saremi N, Hadjati J, Hamblin MR, Mirzaei HR. Chimeric antigen receptor (CAR) T cell therapy for metastatic melanoma: challenges and road ahead. Cells. 2021;10(6):1450.","journal-title":"Cells"},{"issue":"5","key":"1377_CR79","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","volume":"3","author":"PD Shah","year":"2023","unstructured":"Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, et al. Phase i trial of autologous RNA-electroporated cMET-directed CAR t cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res Commun. 2023;3(5):821\u20139.","journal-title":"Cancer Res Commun"},{"key":"1377_CR80","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379. https:\/\/doi.org\/10.1038\/nrd.2017.243.","journal-title":"Nat Rev Drug Discov"},{"key":"1377_CR81","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-021-01329-3","volume":"20","author":"L Van Hoecke","year":"2021","unstructured":"Van Hoecke L, Verbeke R, Dewitte H, Lentacker I, Vermaelen K, Breckpot K, et al. mRNA in cancer immunotherapy: beyond a source of antigen. Mol Cancer. 2021;20:48. https:\/\/doi.org\/10.1186\/s12943-021-01329-3.","journal-title":"Mol Cancer"},{"key":"1377_CR82","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"L Alexandrov","year":"2013","unstructured":"Alexandrov L, Initiative A.P.C.G., Nik-Zainal S, Wedge D, Aparicio SAJR, Behjati S, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415\u201321. https:\/\/doi.org\/10.1038\/nature12477.","journal-title":"Nature"},{"key":"1377_CR83","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045[15]70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment [CheckMate 037]: a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384. https:\/\/doi.org\/10.1016\/S1470-2045[15]70076-8.","journal-title":"Lancet Oncol"},{"key":"1377_CR84","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka E, et al. Nivolumab in previously untreated melanoma withoutbrafmutation. N Engl J Med. 2015;372:320\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1412082.","journal-title":"N Engl J Med"},{"key":"1377_CR85","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.critrevonc.2017.05.001","volume":"115","author":"J Pitcovski","year":"2017","unstructured":"Pitcovski J, Shahar E, Aizenshtein E, Gorodetsky R. Melanoma antigens and related immunological markers. Crit Rev Oncol. 2017;115:36\u201349. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.05.001.","journal-title":"Crit Rev Oncol"},{"key":"1377_CR86","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1158\/1078-0432.CCR-05-2616","volume":"12","author":"FS Hodi","year":"2006","unstructured":"Hodi FS. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006;12:673\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2616.","journal-title":"Clin Cancer Res"},{"key":"1377_CR87","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.humpath.2013.02.007","volume":"45","author":"NG Ord\u00f3\u00f1ez","year":"2014","unstructured":"Ord\u00f3\u00f1ez NG. Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update. Hum Pathol. 2014;45:191\u2013205. https:\/\/doi.org\/10.1016\/j.humpath.2013.02.007.","journal-title":"Hum Pathol"},{"key":"1377_CR88","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/35077246","volume":"411","author":"SA Rosenberg","year":"2001","unstructured":"Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380\u20134. https:\/\/doi.org\/10.1038\/35077246.","journal-title":"Nature"},{"key":"1377_CR89","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","volume":"12","author":"C Barrow","year":"2006","unstructured":"Barrow C, Browning J, MacGregor D, Davis ID, Sturrock S, Jungbluth AA, et al. Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res. 2006;12:764\u201371. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1544.","journal-title":"Clin Cancer Res"},{"key":"1377_CR90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12033-014-9800-y","volume":"57","author":"S Fogal","year":"2015","unstructured":"Fogal S, Carotti M, Giaretta L, Lanciai F, Nogara L, Bubacco L, et al. Human tyrosinase produced in insect cells: a landmark for the screening of new drugs addressing its activity. Mol Biotechnol. 2015;57:45\u201357. https:\/\/doi.org\/10.1007\/s12033-014-9800-y.","journal-title":"Mol Biotechnol"},{"key":"1377_CR91","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jdermsci.2004.08.014","volume":"37","author":"VJ Hearing","year":"2005","unstructured":"Hearing VJ. Biogenesis of pigment granules: a sensitive way to regulate melanocyte function. J Dermatol Sci. 2005;37:3\u201314. https:\/\/doi.org\/10.1016\/j.jdermsci.2004.08.014.","journal-title":"J Dermatol Sci"},{"key":"1377_CR92","first-page":"7577","volume":"61","author":"H Kobayashi","year":"2001","unstructured":"Kobayashi H, Lu J. Identification of helper t-cell epitopes that encompass or lie proximal to cytotoxic t-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res. 2001;61:7577\u201384.","journal-title":"Cancer Res"},{"key":"1377_CR93","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/humrep\/del494","volume":"22","author":"MF Gjerstorff","year":"2007","unstructured":"Gjerstorff MF, Kock K, Nielsen O, Ditzel HJ. MAGE-A1, GAGE and NY-ESO-1 cancer\/testis antigen expression during human gonadal development. Hum Reprod. 2007;22:953\u201360. https:\/\/doi.org\/10.1093\/humrep\/del494.","journal-title":"Hum Reprod"},{"key":"1377_CR94","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/0008-5472.CAN-04-1882","volume":"65","author":"G Cronwright","year":"2005","unstructured":"Cronwright G, Le Blanc K, G\u00f6therstr\u00f6m C, Darcy P, Ehnman M, Brodin B. Cancer\/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005;65:2207\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1882.","journal-title":"Cancer Res"},{"key":"1377_CR95","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s00726-012-1409-5","volume":"43","author":"N Tandler","year":"2012","unstructured":"Tandler N, Mosch B, Pietzsch J. Protein and non-protein biomarkers in melanoma: a critical update. Amino Acids. 2012;43:2203\u201330. https:\/\/doi.org\/10.1007\/s00726-012-1409-5.","journal-title":"Amino Acids"},{"key":"1377_CR96","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2708.","journal-title":"Clin Cancer Res"},{"key":"1377_CR97","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","volume":"114","author":"LA Johnson","year":"2009","unstructured":"Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114:535\u201346. https:\/\/doi.org\/10.1182\/blood-2009-03-211714.","journal-title":"Blood"},{"key":"1377_CR98","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1158\/1078-0432.CCR-0095-03","volume":"10","author":"EB Walker","year":"2004","unstructured":"Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, et al. gp100209\u20132M peptide immunization of human lymphocyte antigen-A2\u2009+\u2009stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8\u2009+\u2009T cells. Clin Cancer Res. 2004;10:668\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-0095-03.","journal-title":"Clin Cancer Res"},{"key":"1377_CR99","doi-asserted-by":"publisher","first-page":"3413","DOI":"10.1172\/JCI80008","volume":"125","author":"MM Gubin","year":"2015","unstructured":"Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest. 2015;125:3413\u201321. https:\/\/doi.org\/10.1172\/JCI80008.","journal-title":"J Clin Invest"},{"key":"1377_CR100","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","volume":"10","author":"ER Cantwell-Dorris","year":"2011","unstructured":"Cantwell-Dorris ER, O\u2019Leary J, Sheils O. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385\u201394. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0799.","journal-title":"Mol Cancer Ther"},{"key":"1377_CR101","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/1758834017708160","volume":"9","author":"A Boespflug","year":"2017","unstructured":"Boespflug A, Caramel J, Dalle S, Thomas L. <article-title update=\"added\"> Treatment of NRAS -mutated advanced or metastatic melanoma: rationale, current trials and evidence to date. Ther Adv Med Oncol. 2017;9:481\u201392. https:\/\/doi.org\/10.1177\/1758834017708160.","journal-title":"Ther Adv Med Oncol"},{"key":"1377_CR102","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2217\/imt-2016-0071","volume":"8","author":"RJ Fecek","year":"2016","unstructured":"Fecek RJ, Storkus WJ. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy. 2016;8:1205\u201318. https:\/\/doi.org\/10.2217\/imt-2016-0071.","journal-title":"Immunotherapy"},{"key":"1377_CR103","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Shuqiang L, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An Immunogenic personal neoantigen vaccine for patients with melanoma. Nat Cell Biol. 2017;547:217\u201321. https:\/\/doi.org\/10.1038\/nature22991.","journal-title":"Nat Cell Biol"},{"key":"1377_CR104","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3389\/fimmu.2017.01807","volume":"8","author":"A Rubinsteyn","year":"2017","unstructured":"Rubinsteyn A, Kodysh J, Hodes I, Mondet S, Aksoy BA, Finnigan JP, et al. Computational pipeline for the PGV-001 neoantigen vaccine trial. Front Immunol. 2017;8:1807. https:\/\/doi.org\/10.3389\/fimmu.2017.01807.","journal-title":"Front Immunol"},{"key":"1377_CR105","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"N Hayward","year":"2017","unstructured":"Hayward N, Wilmott J, Waddell N, Johansson PA, Field M, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380. https:\/\/doi.org\/10.1038\/nature22071.","journal-title":"Nature"},{"key":"1377_CR106","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"4877408","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;4877408:500\u20134.","journal-title":"Nature"},{"key":"1377_CR107","unstructured":"U.S. Food and Drug Administration [FDA] [[accessed on 1 January 2014]];2014 Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/204114s001lbl.pdf"},{"issue":"2","key":"1377_CR108","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R. Improved survival with MEK Inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107\u201314.","journal-title":"N Engl J Med"},{"key":"1377_CR109","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"37120","author":"GV Long","year":"2014","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ. Chiarion sileni V. Combined BRAF and MEK Inhibition versus BRAF Inhibition alone in melanoma. N Engl J Med. 2014;37120:1877\u201388.","journal-title":"N Engl J Med"},{"issue":"7","key":"1377_CR110","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","volume":"381","author":"C Robert","year":"2019","unstructured":"Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H. Five-year outcomes with Dabrafenib plus Trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626\u201336.","journal-title":"N Engl J Med"},{"issue":"7","key":"1377_CR111","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","volume":"18","author":"PA Prieto","year":"2012","unstructured":"Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039\u201347.","journal-title":"Clin Cancer Res"},{"key":"1377_CR112","unstructured":"Blank CU, Lucas MW, Scolyer RA, van de Wiel BA, Menzies AM, Lopez-Yurda M, Hoeijmakers LL, Saw RP, Lijnsvelt JM, Maher NG, Pulleman SM. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. The New England journal of medicine. 2024."},{"key":"1377_CR113","doi-asserted-by":"crossref","unstructured":"Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS. Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma. NEJM Evid. 2022;1(11):EVIDoa2200214.","DOI":"10.1056\/EVIDoa2200214"},{"key":"1377_CR114","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/CMR.0000000000000850","volume":"326","author":"IM Shui","year":"2022","unstructured":"Shui IM, Scherrer E, Frederickson A, Li JW, Mynzhassarova A, Druyts E, Tawbi H. Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the society for immunotherapy of cancer immunotherapy resistance taskforce anti-PD1 resistance definitions. Melanoma Res. 2022;326:393\u2013404.","journal-title":"Melanoma Res"},{"key":"1377_CR115","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"5237559","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;5237559:231\u20135.","journal-title":"Nature"},{"issue":"5","key":"1377_CR116","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1172\/JCI95351","volume":"128","author":"J Nsengimana","year":"2018","unstructured":"Nsengimana J, Laye J, Filia A, O\u2019Shea S, Muralidhar S, Po\u017aniak J, Droop A, Chan M, Walker C, Parkinson L, Gascoyne J. \u03b2-Catenin\u2013mediated immune evasion pathway frequently operates in primary cutaneous melanomas. J Clin Investig. 2018;128(5):2048\u201363.","journal-title":"J Clin Investig"},{"key":"1377_CR117","first-page":"RA235","volume":"1010","author":"EC Chu","year":"2004","unstructured":"Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and cell biology. Med Sci Monitor: Int Med J Experimental Clin Res. 2004;1010:RA235\u201341.","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"key":"1377_CR118","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrm3330","volume":"13","author":"MS Song","year":"2012","unstructured":"Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283\u201396. https:\/\/doi.org\/10.1038\/nrm3330.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"1377_CR119","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","volume":"6","author":"W Peng","year":"2016","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ. Loss of PTEN promotes resistance to T cell\u2013mediated immunotherapy. Cancer Discov. 2016;6(2):202\u201316.","journal-title":"Cancer Discov"},{"issue":"1","key":"1377_CR120","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1038\/s41467-023-36979-y","volume":"14","author":"SY Lim","year":"2023","unstructured":"Lim SY, Shklovskaya E, Lee JH, Pedersen B, Stewart A, Ming Z, Irvine M, Shivalingam B, Saw RP, Menzies AM, Carlino MS. The molecular and functional landscape of resistance to immune checkpoint Blockade in melanoma. Nat Commun. 2023;14(1):1516.","journal-title":"Nat Commun"},{"issue":"3","key":"1377_CR121","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/cancers12030742","volume":"12","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Mitra S, Sanna A, Ekedahl H, L\u00f6vgren K, Olsson H, Ingvar C, Isaksson K, Lauss M, Carneiro A, J\u00f6nsson G. The role of PTEN loss in immune escape, melanoma prognosis and therapy response. Cancers. 2020;12(3):742.","journal-title":"Cancers"},{"issue":"8","key":"1377_CR122","doi-asserted-by":"publisher","first-page":"e002279","DOI":"10.1136\/jitc-2020-002279","volume":"9","author":"S Isoyama","year":"2021","unstructured":"Isoyama S, Mori S, Sugiyama D, Kojima Y, Tada Y, Shitara K, Hinohara K, Dan S, Nishikawa H. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. J Immunother Cancer. 2021;9(8): e002279.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1377_CR123","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/cancers13010134","volume":"13","author":"A Mpakali","year":"2021","unstructured":"Mpakali A, Stratikos E. The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers. 2021;13(1):134.","journal-title":"Cancers"},{"issue":"9","key":"1377_CR124","doi-asserted-by":"publisher","first-page":"e1468955","DOI":"10.1080\/2162402X.2018.1468955","volume":"7","author":"PA Ascierto","year":"2018","unstructured":"Ascierto PA, Dummer R. Immunological effects of BRAF + MEK Inhibition. Oncoimmunology. 2018;7(9): e1468955.","journal-title":"Oncoimmunology"},{"key":"1377_CR125","doi-asserted-by":"publisher","first-page":"661737","DOI":"10.3389\/fimmu.2021.661737","volume":"12","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE. Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: implications for combining targeted therapy and immune checkpoint Blockade for the treatment of melanoma. Front Immunol. 2021;12:661737.","journal-title":"Front Immunol"},{"key":"1377_CR126","doi-asserted-by":"crossref","unstructured":"Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma. Sci Transl Med. 2015;7(279):279ra41-.","DOI":"10.1126\/scitranslmed.aaa4691"},{"issue":"2","key":"1377_CR127","doi-asserted-by":"publisher","first-page":"e001806","DOI":"10.1136\/jitc-2020-001806","volume":"8","author":"PF Ferrucci","year":"2020","unstructured":"Ferrucci PF, Di Giacomo AM, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens R, Svane IM, Lotem M. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and Trametinib in BRAF-mutant melanoma. J Immunother Cancer. 2020;8(2): e001806.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1377_CR128","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41467-023-44475-6","volume":"15","author":"PA Ascierto","year":"2024","unstructured":"Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandal\u00e0 M, Ferrucci PF, Guidoboni M, Rutkowski P. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun. 2024;15(1):146.","journal-title":"Nat Commun"},{"issue":"22","key":"1377_CR129","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.3390\/cancers13225788","volume":"13","author":"F Varrone","year":"2021","unstructured":"Varrone F, Mandrich L, Caputo E. Melanoma immunotherapy and precision medicine in the era of tumor micro-tissue engineering: where are we now and where are we going? Cancers. 2021;13(22):5788.","journal-title":"Cancers"},{"issue":"8","key":"1377_CR130","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell F, Berger TR, Maus MV. Understanding CAR t cell-tumor interactions: paving the way for successful clinical outcomes. Med. 2022;3(8):538\u201364.","journal-title":"Med"},{"key":"1377_CR131","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/aac2.70000","volume":"62","author":"SS Beniwal","year":"2025","unstructured":"Beniwal SS, Radhakrishnan AC, Haripraba A, Syed S, Pragna G, Dwivedi A, Rawat A, Calder\u00f3n DC, Cevallos-Cueva M. Understanding and overcoming immunotherapy resistance in skin cancer: mechanisms and strategies. Aging Cancer. 2025;62:33\u201345.","journal-title":"Aging Cancer"},{"key":"1377_CR132","doi-asserted-by":"publisher","first-page":"956090","DOI":"10.3389\/fimmu.2022.956090","volume":"13","author":"JL Huo","year":"2022","unstructured":"Huo JL, Wang YT, Fu WJ, Lu N, Liu ZS. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022;13:956090.","journal-title":"Front Immunol"},{"key":"1377_CR133","unstructured":"Ascierto PA, Melero I, Bhatia S, Bono P, Sanborn RE, Lipson EJ, Callahan MK, Gajewski T, Gomez-Roca CA, Hodi FS, Curigliano G. Initial efficacy of anti-lymphocyte activation gene-3 [anti\u2013LAG-3; BMS-986016] in combination with nivolumab [nivo] in Pts with melanoma [MEL] previously treated with anti\u2013PD-1\/PD-L1 therapy."},{"issue":"1","key":"1377_CR134","doi-asserted-by":"publisher","first-page":"e000911","DOI":"10.1136\/jitc-2020-000911","volume":"8","author":"N Acharya","year":"2020","unstructured":"Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape. J Immunother Cancer. 2020;8(1): e000911.","journal-title":"J Immunother Cancer"},{"key":"1377_CR135","unstructured":"Mooradian M, Karunamurthy A, Wang H, Buchbinder EI, Rapisuwon S, Cohen JV, Gibney GT, Sullivan RJ, Luke JJ, Najjar YG, Kirkwood JM. Randomized phase II study of neoadjuvant [neoadj] anti-PD-1 dostarlimab [D] vs. D\u2009+\u2009anti-TIM-3 cobolimab [C] in high-risk resectable melanoma [mel][NEO-MEL-T]: Primary analysis."},{"issue":"6","key":"1377_CR136","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, Park S, Javinal V, Chiu H, Irving B, Eaton DL. The immunoreceptor TIGIT regulates antitumor and antiviral CD8 + T cell effector function. Cancer Cell. 2014;26(6):923\u201337.","journal-title":"Cancer Cell"},{"key":"1377_CR137","doi-asserted-by":"publisher","first-page":"155468","DOI":"10.1016\/j.prp.2024.155468","volume":"260","author":"S Ledderose","year":"2024","unstructured":"Ledderose S, Ledderose C, Ledderose GJ. Expression of immune checkpoint molecules TIGIT and TIM-3 by tumor-infiltrating lymphocytes predicts poor outcome in sinonasal mucosal melanoma. Pathology-Research Pract. 2024;260:155468.","journal-title":"Pathology-Research Pract"},{"key":"1377_CR138","doi-asserted-by":"crossref","unstructured":"Valdez-Salazar F, Jim\u00e9nez-Del Rio LA, Padilla-Guti\u00e9rrez JR, Valle Y, Mu\u00f1oz-Valle JF. Vald\u00e9s-Alvarado E. Advances in melanoma: from genetic insights to therapeutic innovations. Biomedicines. 2024;12(8):1851.","DOI":"10.3390\/biomedicines12081851"},{"key":"1377_CR139","doi-asserted-by":"publisher","first-page":"1281940","DOI":"10.3389\/fimmu.2024.1281940","volume":"15","author":"J Li","year":"2024","unstructured":"Li J, Dan K, Ai J. Machine learning in the prediction of immunotherapy response and prognosis of melanoma: a systematic review and meta-analysis. Front Immunol. 2024;15:1281940.","journal-title":"Front Immunol"},{"issue":"24","key":"1377_CR140","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.3390\/cells11243965","volume":"11","author":"A Guerrisi","year":"2022","unstructured":"Guerrisi A, Falcone I, Valenti F, Rao M, Gallo E, Ungania S, Maccallini MT, Fanciulli M, Frascione P, Morrone A, Caterino M. Artificial intelligence and advanced melanoma: treatment management implications. Cells. 2022;11(24):3965.","journal-title":"Cells"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01377-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01377-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T10:02:40Z","timestamp":1768816960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01377-7"}},"subtitle":["Author List"],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01377-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent\u00a0<!--Emphasis Type='Bold' removed-->Statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}